Comparative analysis of serum proteomes of degenerative scoliosis

Journal of Orthopaedic Research

Volumn 29, Issue 12, 2011, Pages 1896-1903

  Zhu, Yong ^a   Han, Shijie ^b   Zhao, Hong ^b   Liang, Jinqian ^b   Zhai, Jiliang ^b   Wu, Zhihong ^b   Qiu, Guixing ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

degenerative; DIGE; proteomics; scoliosis; serum

Indexed keywords

ALBUMIN; CLUSTERIN; COMPLEMENTARY DNA; FICOLIN 3; G PROTEIN REGULATED INDUCER OF NEURITE OUTGROWTH 1; GENE PRODUCT; HLA ANTIGEN CLASS 1; HYPOTHETICAL SHORT PROTEIN; ISOPROTEIN; MOLECULAR MARKER; PROTEIN; PROTEOME; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DEGENERATIVE DISEASE; DOWN REGULATION; FEMALE; FLUORESCENCE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCOLIOSIS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PROTEOME; PROTEOMICS; SCOLIOSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPINAL STENOSIS;

EID: 80054711186     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21466     Document Type: Article

References (33)

1. Ploumis A, Transfledt EE, Denis F., 2007. Degenerative lumbar scoliosis associated with spinal stenosis. Spine 7: 428-436. (Pubitemid 47040671)
2. Vanderpool DW, James JIP, Wynne-Davies R., 1969. Scoliosis in the elderly. J Bone Joint Surg 51: 446-455.
3. Robin GC, Span Y, Steinberg R, et al. 1982. Scoliosis in the elderly. A follow-up study Spine 7: 355.
4. Marouga R, David S, Hawkins E., 2005. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382: 669-678. (Pubitemid 40890994)
5. Van den Bergh G, Arckens L., 2004. Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol 15: 38-43. (Pubitemid 38224247)
6. Jurkunas UV, Bitar MS, Rawe I, et al. 2008. Increased clusterin expression in Fuchs' endothelial dystrophy. Invest Ophthalmol Vis Sci 49: 2946-2955.
7. Looi ML, Karsani SA, Rahman MA, et al. 2009. Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J Biosci 34: 917-925.
8. Alexopoulos EC, Cominos X, Trougakos IP, et al. 2008. Biological monitoring of hexavalent chromium and serum levels of the senescence biomarker apolipoprotein J/clusterin in welders. Bioinorg Chem Appl 420578, p. 1-6.
9. Høg̊sen K, Mollnes TE, Harboe M, et al. 1995. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 22: 24-28.
10. Trougakos IP, Gonos ES., 2002. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34: 1430-1438.
11. Petropoulou C, Trougakos IP, Kolettas E, et al. 2001. Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett 509: 287-297. (Pubitemid 34015959)
12. Bettuzzi S, Scorcioni F, Astancolle S, et al. 2002. Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21: 4328-4334. (Pubitemid 34753840)
13. Poon S, Treweek TM, Wilson MR, et al. 2002. Clusterin is an extracellular chaperone that specifically interacts with slowly aggregating proteins on their off-folding pathway. FEBS Lett 513: 259-266. (Pubitemid 34251275)
14. Matsuda A, Itoh Y, Koshikawa N, et al. 2003. Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J Biol Chem 278: 36350-36357. (Pubitemid 37139962)
15. Devauchelle V, Essabbani A, De Pinieux G, et al. 2006. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J Immunol 177: 6471-6479. (Pubitemid 44628866)
16. McLaughlin L, Zhu G, Mistry M, et al. 2000. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest 106: 1105-1113.
17. Newkirk MM, Apostolakos P, Neville C, et al. 1999. Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an antiinflammatory protein. J Rheumatol 26: 597-603. (Pubitemid 29125578)
18. Nakata H, Kozasa T., 2005. Functional characterization of Gαo signaling through G protein-regulated inducer of neurite outgrowth 1. Mol Pharmacol 67: 695-702. (Pubitemid 40365317)
19. Chen LT, Gilman AG, Kozasa T., 1999. A candidate target for G protein action in brain. J Biol Chem 274: 26931-26938.
20. Masuho I, Mototani Y, Sahara Y, et al. 2008. Dynamic expression patterns of G protein-regulated inducer of neurite outgrowth 1 (GRIN1) and its colocalization with Gαo implicate significant roles of Gαo-GRIN1 signaling in nervous system. Dev Dyn 237: 2415-2429.
21. Zhao X, Li H, Shi Y, et al. 2006. Significant association between the genetic variations in the 5′ end of the N-methyl- D -aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 59: 747-753.
22. Puppo F, Scudeletti M, Indiveri F, et al. 1995. Serum HLA class I antigens: markers and modulators of an immune response ? Immunol Today 16: 124-127.
23. Carbone E, Terrazzano G, Colonna M, et al. 1996. Natural killer cell clones recognize specific soluble HLA class I molecules. Eur J Immunol 26: 683-689. (Pubitemid 26091400)
24. Nocito M, Montalbán C, González-Porque P, et al. 1997. Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol 58: 106-111. (Pubitemid 28093581)
25. Muñoz-Fernández S, Martín J, Martín-Mola E, et al. 2001. Soluble HLA class I antigens in serum and synovial fluid from patients with rheumatoid arthritis and other arthropathies. Rheumatology 40: 1365-1369.
26. McDonald JC, Adamashvili I., 1998. Soluble HLA: a review of the literature. Hum Immunol 59: 387-403. (Pubitemid 28332489)
27. Yae Y, Inaba S, Sato H, et al. 1991. Isolation and characterization of a thermolabile beta-2 macroglycoprotein ('thermolabile substance' or 'Hakata antigen') detected by precipitating (auto) antibody in sera of patients with systemic lupus erythematosus. Biochim Biophys Acta 1078: 369-376.
28. Munthe-Fog L, Hummelshoj T, Ma YJ, et al. 2008. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a ficolin-3 (Hakata antigen) deficiency state. Mol Immunol 45: 2660-2666.
29. Munthe-Fog L, Hummelshoj T, Hansen BE, et al. 2007. The impact of FCN2 polymorphisms and haplotypes on the ficolin-2 serum levels. Scand J Immunol 65: 383-392. (Pubitemid 46481107)
30. Hummelshoj T, Fog LM, Madsen HO, et al. 2008. Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). Mol Immunol 45: 1623-1632. (Pubitemid 351221142)
31. Schlapbach LJ, Aebi C, Hansen AG, et al. 2009. H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients. Clin Exp Immunol 157: 83-89.
32. Munthe-Fog L, Hummelshøj T, Honoré C, et al. 2009. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med 360: 2637-2644.
33. Honore C, Hummelshoj T, Hansen BE, et al. 2007. The innate immune component ficolin 3 (Hakata Antigen) mediates the clearance of late apoptotic cells. Arthritis Rheum 56: 1598-1607. (Pubitemid 46764089)